JFG
KYMR icon

Jefferies Financial Group’s Kymera Therapeutics KYMR Stock Holding History

Jefferies Financial Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,200
Closed -$573K – 1616
2024
Q2 		$573K Sell
19,200
-4,800
-20% -$166K 0.01% 925
2024
Q1 		$965K Hold
24,000
– – 0.01% 840
2023
Q4 		$611K Sell
24,000
-940
-4% -$16.8K ﹤0.01% 1137
2023
Q3 		$347K Buy
+24,940
New +$501K ﹤0.01% 1196
2023
Q2 		– Sell
-84,492
Closed -$2.5M – 1867
2023
Q1 		$2.5M Buy
+84,492
New +$2.72M 0.02% 582

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jefferies Financial Group's KYMR Position: Q3 2024 in Review

Jefferies Financial Group sold out of Kymera Therapeutics (KYMR) in Q3 2024, closing a stake of 19,200 shares — an estimated $573K sold.

Jefferies Financial Group first reported a position in KYMR in Q1 2023 and held it in 5 quarters. The position peaked at $2.5M in Q1 2023. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • Jefferies Financial Group reported no remaining Kymera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 19,200 Kymera Therapeutics shares in Q3 2024, an estimated $573K.
  • Jefferies Financial Group first reported a position in Kymera Therapeutics in Q1 2023 and held it in 5 quarters.
  • Jefferies Financial Group's Kymera Therapeutics position peaked at $2.5M in Q1 2023.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on Jefferies Financial Group's 13F filing for Q3 2024, filed 14 Nov 2024.